Repaglinide

Warning

Hypoglycemia is a common adverse reaction, and patients should be instructed on how to manage it.

Contraindications

• Concomitant use of gemfibrozil
• Known hypersensitivity to repaglinide
• Severe renal impairment

Adverse Reactions

• Hypoglycemia
• Upper respiratory infection
• Headache
• Sinusitis

General Guidance

The dose should be adjusted based on the patient's response to therapy, and the maximum daily dose should not exceed 16 mg.

Pregnancy

• Limited data available on the use of repaglinide during pregnancy
• Repaglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Nursing Mothers

• It is not known whether repaglinide is excreted in human milk
• Caution should be exercised when repaglinide is administered to a nursing woman

Pediatric Use

• Safety and effectiveness have not been established in pediatric patients

Geriatric Use

• No differences in effectiveness or adverse events were seen in patients over 65 years of age compared to those less than 65
• Greater sensitivity of some older individuals to repaglinide cannot be ruled out